HK1252172A1 - 用於使用stat3途徑抑制劑和激酶抑制劑治療癌症的方法 - Google Patents

用於使用stat3途徑抑制劑和激酶抑制劑治療癌症的方法

Info

Publication number
HK1252172A1
HK1252172A1 HK18111573.2A HK18111573A HK1252172A1 HK 1252172 A1 HK1252172 A1 HK 1252172A1 HK 18111573 A HK18111573 A HK 18111573A HK 1252172 A1 HK1252172 A1 HK 1252172A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor
methods
treating cancer
stat3 pathway
kinase inhibitor
Prior art date
Application number
HK18111573.2A
Other languages
English (en)
Inventor
Chiang J Li
Youzhi Li
Harry Rogoff
Yuan Gao
Janet Huang
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of HK1252172A1 publication Critical patent/HK1252172A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18111573.2A 2015-04-27 2018-09-07 用於使用stat3途徑抑制劑和激酶抑制劑治療癌症的方法 HK1252172A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562153385P 2015-04-27 2015-04-27

Publications (1)

Publication Number Publication Date
HK1252172A1 true HK1252172A1 (zh) 2019-05-17

Family

ID=56081544

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111573.2A HK1252172A1 (zh) 2015-04-27 2018-09-07 用於使用stat3途徑抑制劑和激酶抑制劑治療癌症的方法

Country Status (16)

Country Link
US (1) US20180250261A1 (zh)
EP (1) EP3288552A1 (zh)
JP (2) JP2018514557A (zh)
KR (1) KR20170141716A (zh)
CN (1) CN107683137A (zh)
AU (1) AU2016255034A1 (zh)
BR (1) BR112017022958A2 (zh)
CA (1) CA2983468A1 (zh)
EA (1) EA201792320A1 (zh)
HK (1) HK1252172A1 (zh)
IL (1) IL255023A0 (zh)
MX (1) MX2017013816A (zh)
PH (1) PH12017501882A1 (zh)
SG (1) SG11201708506QA (zh)
TW (1) TW201713329A (zh)
WO (1) WO2016176190A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732055B2 (en) 2007-09-10 2017-08-15 Boston Biomedical, Inc. Compositions and methods for cancer treatment
RU2015147696A (ru) 2013-04-09 2017-05-12 Бостон Байомедикал, Инк. Способы лечения злокачественной опухоли
CA3029596A1 (en) * 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
WO2022178957A1 (zh) * 2021-02-25 2022-09-01 毕庶壮 Napabucasin的制药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2197878T (lt) * 2007-09-06 2016-09-26 Boston Biomedical, Inc. Kinazės inhibitorių kompozicijos ir jų panaudojimas vėžio ir kitų su kinazėmis susijusių ligų gydymui
US9732055B2 (en) 2007-09-10 2017-08-15 Boston Biomedical, Inc. Compositions and methods for cancer treatment
RU2015147696A (ru) * 2013-04-09 2017-05-12 Бостон Байомедикал, Инк. Способы лечения злокачественной опухоли

Also Published As

Publication number Publication date
TW201713329A (zh) 2017-04-16
PH12017501882A1 (en) 2018-03-05
EP3288552A1 (en) 2018-03-07
WO2016176190A1 (en) 2016-11-03
JP2021121629A (ja) 2021-08-26
KR20170141716A (ko) 2017-12-26
JP2018514557A (ja) 2018-06-07
CA2983468A1 (en) 2016-11-03
SG11201708506QA (en) 2017-11-29
BR112017022958A2 (pt) 2018-07-17
MX2017013816A (es) 2018-11-12
IL255023A0 (en) 2017-12-31
EA201792320A1 (ru) 2018-02-28
US20180250261A1 (en) 2018-09-06
AU2016255034A1 (en) 2017-11-02
CN107683137A (zh) 2018-02-09

Similar Documents

Publication Publication Date Title
IL279258B (en) tyrosine kinase inhibitors
HRP20181899T1 (hr) Biaril inhibitori kinaze
HK1245677A1 (zh) 用於治療炎症和癌症的雜環itk抑制劑
HK1251407A1 (zh) 治療癌症的方法
HK1249469A1 (zh) 用RORγ抑制劑治療癌症的方法
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
HK1252172A1 (zh) 用於使用stat3途徑抑制劑和激酶抑制劑治療癌症的方法
SI3371165T1 (sl) Zaviralec BTK za uporabo pri zdravljenju raka
EP3131552A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1250944A1 (zh) 用於治療癌症的方法
IL265139B (en) Dopamine-b-hydroxylase inhibitors
HK1250942A1 (zh) 用於治療癌症的方法
GB201612860D0 (en) Inhibitors
HK1250943A1 (zh) 用於治療癌症的方法
EP3131550A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
GB201519381D0 (en) Kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201614783D0 (en) Kinases inhibitors